DOCUMENT RESOURCES FOR EVERYONE
Documents tagged
Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in Hyperlipidemic Subjects: A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled.
Documents Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in Hyperlipidemic Subjects: A 52 Week...

Slide 1Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in Hyperlipidemic Subjects: A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled Study Dirk Blom,…

Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145: 52-Week Results From the OSLER Study Michael J.
Documents Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG.....

Slide 1 Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145: 52-Week Results From the OSLER Study Michael J Koren 1, Robert…

Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a Randomized, Double-blind, Placebo- Controlled.
Documents Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS):...

Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a Randomized, Double-blind, Placebo-Controlled Study Evan A. Stein1,…

Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?
Documents Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution? Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution? Patient…

A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of a Monoclonal Antibody to PCSK9, SAR236553/REGN727, in Patients with.
Documents A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of a Monoclonal...

A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of a Monoclonal Antibody to PCSK9, SAR236553/REGN727, in Patients with Primary Hypercholesterolemia…

Presenter Disclosure Information
Documents Presenter Disclosure Information

Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a Randomized, Double-blind, Placebo-Controlled Study Evan A. Stein1,…

Dirk Blom, Tomas Hala, Michael Bolognese, Michael J Lillestol, Phillip D Toth, Lesley Burgess, Richard Ceska , Eli Roth,
Documents Dirk Blom, Tomas Hala, Michael Bolognese, Michael J Lillestol, Phillip D Toth, Lesley Burgess,...

PowerPoint Presentation Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in Hyperlipidemic Subjects: A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled…

November 19, 2013, Session CS.03 American Heart Association Scientific Sessions, Dallas, TX
Documents November 19, 2013, Session CS.03 American Heart Association Scientific Sessions, Dallas, TX

Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145: 52-Week Results From the OSLER Study Michael J Koren1, Robert P Giugliano2,…

Clinicaltrials no. NCT01288443
Documents Clinicaltrials no. NCT01288443

A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of a Monoclonal Antibody to PCSK9, SAR236553/REGN727, in Patients with Primary Hypercholesterolemia…

Popular Categories
Relevant Tags